Kornimate/medical-research-clean huggingface dataset:
exploring the effectiveness of ai generative models for diabetic patients

Conditions: Diabetes Mellitus, Type 2; Diabetic Retinopathy; Diabetes

Summary: we plan to explore the usability of generative ai-chatbot for diabetic patient

diabetes is rapidly spreading, affecting a significant number of adults, with a staggering total of 537 million diabetic individuals. this condition gives rise to various complications that can lead to diabetic retinopathy, foot ulcers, cardiac problems, and kidney damage. however, many of these complications can be mitigated by providing patients with accurate information concerning their diet, stress management, and weight control. the recent advancements in generative artificial intelligence-based chatbots have demonstrated their efficacy as intelligent assistants across various aspects of human life. in this study, we aim to assess the effectiveness of these language models in assisting patients. our research plan entails the interaction between patients and chatbots like chatgpt, both with and without human support, followed by evaluations of these interactions by specialists. additionally, we will gather feedback from patients regarding their experiences and perceptions of the chatbot interactions.

Eligibility criteria:
inclusion criteria: * present physically in pakistan * adults (18 years or older) * diabetic patient exclusion criteria: * adults unable to consent * individuals who are not yet adults (infants, children, teenagers) * prisoners
effect of mobilization with movement on weight bearing ankle dorsiflexion range of motion

Conditions: Ankle Joint Contracture

Summary: limited ankle range of motion is associated with increased risk for ankle sprains, knee joint dysfunction and injury to the acl. therefore, it is important that researchers and clinicians understand the best treatment options to increase ankle range of motion for injury prevention. we are recruiting adults with limited ankle range of motion who are lacking current ankle injuries for a treatment investigation. all study procedures will occur on the campus of the university of south carolina by a licensed physical therapist and experienced researcher.

all participants will receive the mwm intervention with weight bearing ankle dorsiflexion range of motion measured prior to the intervention, immediately following the intervention, and 24 hours (+/- 3 hours) following the intervention. the participant will first place their foot on a 16-inch box to assist in performance of the intervention by the therapist. a licensed physical therapist (pt) will then stabilize the talus for a proper joint mobilization to be performed. the therapist will then mobilize the distal tib/fib in the posterior to anterior direction at end range df reached through a forward lunge, using a mulligan's mobilization belt around the distal tibia-fibula. the participant will perform 3 sets of 10 repetitions of the forward lunge and the pt will perform a bout of overpressure at end range during each repetition. two other investigators will be on either side of participant to assist with balance during the intervention if needed. weight bearing ankle dorsiflexion range of motion will be measured via a primary and secondary measure. the primary measurement will be use of a bubble inclinometer and the secondary measurement will be the standing ankle dorsiflexion screen (sads).

Eligibility criteria:
inclusion criteria: * the sole inclusion criterion will be a limitation in active ankle dorsiflexion range of motion to less than 20 degrees in weight bearing in one or both ankles. exclusion criteria: * exclusion criteria include self identified feelings of ankle instability or known diagnosis of chronic ankle instability, dermatologic conditions such as open wounds or impaired sensation which inhibit the ability to use the mobilization strap, and inability to get into the testing position or perform a lunge during the intervention.
optical coherence tomography quantitative analysis of changes in anterior chamber after laser peripheral lridotomy

Conditions: Primary Angle Closure Glaucoma

Summary: the purpose of this study is to analysis changes in anterior segment morphology after laser peripheral lrldotomy measured by optical coherence tomography, and to evaluate treatment effectiveness

in the study ,primary angle closure(pac) and primary angle closure glaucoma (pacg) will be recruited. anterior segment optical coherence tomography images captured before and after laser peripheral iridotomy will be analysed to provide objective and reproducible quantification of anterior segment biometric parameters.the outcomes can provide useful information for clinical strategies in the treatment and management of pathology related to angle closure.

Eligibility criteria:
inclusion criteria: 1 .the gonioscopy or ubm examination has confirmed the diagnosis of pacs or pac 2. intraocular pressure within 10 to 21 mmhg ，c/d≤0.6 3. visual field is normal or only show paracentral scotoma 4. vision or corrected visual acuity ≥0.8 5. refractive degree no more than 200d 6. exclude other ocular and systemic diseases - exclusion criteria: 1. corneal macula and other corneal diseases, ocular surface disease or corneal edema 2. iridocyclitis 3. ocular trauma and intraocular operation history 4. no fixationfundus lesions such as diabetic retinopathy or retinal detachment 5. no fixation 6. ocular or systemic application of cortical steroids -
cannulation of the artery axiliaris for extracorporeal circulation

Conditions: Neurologic Manifestations

Summary: comparision of two different cannulation techniques on the neurological outcome in cardiac surcical procedures. study hypothesis: cannulation of the axilaris artery can reduce neurolocical side effects.


Eligibility criteria:
inclusion criteria: * cardiac procedure with ecc age 40-85 years cabg and/or valve exclusion criteria: * stenosis of a.subclavia
impact of imri on the extent of resection in patients with newly diagnosed glioblastomas

Conditions: Glioblastoma

Summary: standard treatment of glioblastomas (gbms) consists of microsurgical resection followed by concomitant chemoradiation. the extent of resection is one of the most important prognostic factors with significant influence on the survival of patients. state of the art technique to achieve the most radical resection possible in conventional surgery is fluorescence-guidance with 5-aminolevulinic acid (5-ala). if available, intraoperative mri (imri)-guided tumor resection enables an intraoperative resection control and subsequent continuation of surgery if contrast enhancing tumor remnants are found. therefore a more radical resection and longer survival of patients might be possible. to date no comparison of these two leading technologies for gbm-surgery is available to identify the best surgical therapy of this fatal disease and to justify significant healthcare-economic differences between both technologies. goal of this study is to assess the value of imri guidance in the resection of gbms in comparison to conventional 5-ala microsurgery. primary endpoint is the number of total resections (no residual contrast enhancement) in the postoperative mri (t1+cm within 48 hours after surgery) in each group. secondary endpoints are perioperative clinical data, progression free survival, patients' clinical condition and overall survival. the study design was chosen to be a parallel-group approach to compare imri and 5-ala centers (n=13) to exclude possible bias which might be found by randomizing patients within individual imri centers and to have surgeons with the most experience possible in use of each respective technology.


Eligibility criteria:
inclusion criteria: 1. in mri suspected primary singular untreated gbm 2. planned total resection of the tumor according to the surgeon 3. patient ≥18 years, ≤80 years 4. preoperative kps ≥ 60%, american society of anesthesiologists (asa) score 1 and 2 5. patients' informed consent exclusion criteria: 1. tumors of the midline, basal ganglia, cerebellum, brain stem, eloquent areas 2. multifocal glioblastoma 3. substantial (\>50%), non-contrast enhancing tumor areas suggesting low-grade glioma with malignant transformation 4. contraindications to mri 5. inability to give consent because of language barrier or dysphasia 6. histological diagnosis other than glioblastoma multiforme who °iv 7. increased risk of thrombosis (e.g. factor v leiden) 8. pregnancy or breast feeding 9. hypersensibility for 5-ala oder porphyrins 10. acute or chronic porphyria 11. renal insufficiency 12. hepatic insufficiency 13. high likelihood of inability to receive adjuvant therapy

Keywords: 5-ala intraoperative mri extent of resection
a clinical trial to evaluate the vision correction safety and efficacy of dsihy silicone hydrogel soft contact lens

Conditions: Myopia; Refractive Errors

Summary: this is a prospective, randomized, double-blind, parallel, active-controlled, multi-center clinical study. the purpose is to evaluate the safety and effectiveness wearing "dsihy silicone hydrogel soft contact lens". subjects will be randomized in 1:1 ratio to wear either the investigational device "dsihy silicone hydrogel soft contact lens" or the control device daily silicone hydrogel contact lenses(ob)".


Eligibility criteria:
inclusion criteria: 1. must be 18 years of age inclusive 2. beside myopia and astigmatism, subjects with normal eyes and are not using any ocular medications (excluding ocular lubricants and artificial tears) 3. best spectacle corrected visual acuity greater than or equal to 1.0 for both eyes 4. with +8.00d \~ -12.00 d spherical component myopia, and ≤1.00 astigmatism (based on manifest refraction measurements) 5. have worn soft contact lens for at least 2 month prior to the study 6. willing to comply with the required wearing time 7. agree to comply with all study procedures, sign and date the informed consent form before starting the clinical study exclusion criteria: 1. anterior segment infection, inflammation or abnormality 2. any active ocular disease that would affect contact lens wear or vision (such as acute and subacute inflammation of the anterior chamber of the eye, eye infection, uveitis, serious palpebral abnormality, corneal hypoesthesia, corneal epithelium abrasion, dry eye and tear duct defection, ocular allergies, highly suspected glaucoma) upon evaluation by the investigators or slit lamp findings 3. currently using systemic or ocular medications that would contraindicate contact lens wear (such as glaucoma eye drops, steroid anti-inflammatory drops, eye ointments, eye gels and other eye medicines) 4. history of herpetic keratitis 5. history of refractive surgery, keratoconus or irregular cornea 6. slit lamp findings that are not suitable for inclusion (details of the grading standards for each eye condition are specified in cip section 5.7.5) 7. a pathologically dry eye (schirmer test 1 \<5 mm) 8. have participated in any contact lens or contact lens care product clinical trials within the previous 1 month (excluding questionnaire types and specimen collection) 9. currently pregnant, lactating, or planning to be pregnant during the trial 10. have experienced discomfort when wearing silicone hydrogel contact lens, or a known allergy to hyaluronic acid and sodium alginate 11. corrected visual acuity in either eye does not reach 1.0 when wearing the trial lens 12. subjects who are judged by the investigators as unsuitable for the study

Keywords: contact lens
nsaid drug interaction study

Conditions: Gout

Summary: this is a drug-drug interaction study in healthy volunteers to evaluate the potential pharmacokinetic (pk) effects of non-steroidal anti-inflammatory drugs on lesinurad and leinurad on the non-steroidal anti-inflammatory drugs.

naproxen and indomethacin are non-steroidal anti-inflammatory drugs (nsaids) used both prophylactically for the prevention of, and as a treatment for, acute gout flares. rdea594-126 is an open-label study designed to assess the potential effect of multiple doses of naproxen and indomethacin on the single-dose pk of lesinurad, and to assess the potential effect of multiple doses of lesinurad on the multiple-dose pk of naproxen and indomethacin.

Eligibility criteria:
inclusion criteria: * subject has a body weight ≥ 50 kg (110 lbs) and a body mass index (bmi) ≥ 18 and ≤ 30 kg/m2. * subject is free of any clinically significant disease that requires a physician's care and/or would interfere with study evaluations or procedures. * subject has no clinically relevant abnormalities in vital signs, ecg, physical examination or safety laboratory values. exclusion criteria: * subject has clinically significant pulmonary, cardiovascular, gastrointestinal, neurologic, hepatic, renal, urological, or psychiatric disorders. * subject has a history or suspicion of kidney stones. * subject has a history of asthma. * subject has undergone major surgery within 3 months prior to day 1. * subject has donated blood or experienced significant blood loss (\> 450 ml) within 12 weeks prior to day 1 or gave a plasma donation within 4 weeks prior to the screening visit. * subject has inadequate venous access or unsuitable veins for repeated venipuncture.
anxiety in black men with prostate cancer: validation of the memorial anxiety scale for prostate cancer in an sample of black men

Conditions: Prostate Cancer

Summary: this study is being done to see if a standard tool used to check anxiety in white men works well for black men. the tool is used only for men who have prostate cancer. it is meant to see how the cancer affects men. if the investigators have a good tool, it is more likely that the investigators can help those who have high levels of anxiety. this test is known as the memorial anxiety scale for prostate cancer (also called the max-pc).


Eligibility criteria:
inclusion criteria: * 18 years of age or older * patients who are being monitored by psa tests, who will have a psa test done on the day of their current clinic visit or prior to their clinic visit, but prior to being informed of the results * diagnosis of prostate cancer * ethnicity: black, african-american, or of african descent (and will include those men who identify as black and hispanic). * ability to comprehend and complete questionnaires in english exclusion criteria: * major psychopathology or cognitive impairment likely, in the judgment of the research staff, to interfere with the participation or completion of the protocol * other non-black or non-african-american ethnic groups

Keywords: anxiety black men prostate cancer 07-125
implementing pharmacogenetic testing in gastrointestinal cancers

Conditions: Gastrointestinal Cancer

Summary: pharmacogenomics (pgx) is the study of how genes affect a person's response to drugs. pgx testing for certain genes can help predict the risk of side effects from chemotherapy agents. testing is not regularly performed in clinical practice due to long wait times for results and challenges with integrating test results in the electronic health record. investigators leading this study hope to find out if providing cancer care providers with the ability to order a pgx test and electronically receive results with dosing recommendations will increase the use of these tests to guide treatment decisions and improve patient outcomes. this is a non-randomized implementation study, which means that all participants in this study will undergo genotyping for a pharmacogenetic test. the investigators will primarily measure the feasibility of using this test to guide cancer care.


Eligibility criteria:
inclusion criteria: 1. able and willing to provide informed consent 2. male or female, aged 18 years or older at the time of study initiation 3. pathologically confirmed gastrointestinal malignancy for which treatment with a fluoropyrimidine and/or irinotecan is indicated 4. willing to undergo blood or saliva sampling for pgx testing and comply with all study-related procedures 5. life expectancy of at least 6 months exclusion criteria: 1. prior treatment with irinotecan 2. dpyd or ugt1a1 genotype already known 3. severe renal or hepatic impairment (or unacceptable laboratory values), including: * neutrophil count of \<1.5 x 109/l, platelet count of \<100 x 109/l * hepatic function as defined by serum bilirubin \>1.5 x upper limit of normal (uln), alanine aminotransferase (alt), and aspartate aminotransferase (ast) \>2.5 x uln, or in case of liver metastases alt and ast\>5 x uln * renal function as defined by serum creatinine \>1.5 x uln, or creatinine clearance \<60 ml/min (by cockcroft-gault equation) 4. women who are pregnant or breast feeding, or subjects who refuse to use reliable contraceptive methods throughout the study 5. treating physician does not want subject to participate

Keywords: gastrointestinal neoplasms fluorouracil capecitabine irinotecan fluoropyrimidines topoisomerase i inhibitors antimetabolites, antineoplastics molecular mechanisms of pharmacological action
pro-resolving effect of mag-dha in cystic fibrosis (premdic)

Conditions: Cystic Fibrosis

Summary: monoglyceride of dha (dha-mag) is a lipid compound for which intestinal absorption would increase the ratio dha / arachidonic acid (aa) and promote the synthesis of specific metabolites involved in the resolution of inflammation. the premdic project, initiated at the centre hospitalier universitaire de sherbrooke, is a randomized double-blind study for people with cystic fibrosis (cf) and aims to evaluate whether daily supplementation monoglyceride of dha (a fatty acid omega-3 family) will reduce lung inflammation and improve pulmonary function.

the goal of the study is: to investigate the efficacity of oral administration of mag-dha to increase dha bioavailability and reduce lung inflammation of patients with cystic fibrosis the specific objectives of the project are : * determine the effect of mag-dha on lipid membranes of the blood mononuclear cells. * evaluate the effect of mag-dha on lung inflammation (determination of human leukocyte elastase and alpha1 antitrypsin complexes : phle). for this study, 20 cystic fibrosis patients are recruited. patients are divided into 2 groups of 10 and received a daily dose equivalent to 3 g of placebo (sunflower oil) or mag-dha. the project takes place over a period of 3 months and patients must travel to the research center for a total of five visits including recruitment. for the 2 groups, dha ratio / aa is measured in membranes of mononuclear cells. forced expiratory volume in 1 second (fev1) is determined and phle complexes are detected in plasma as a marker of inflammation.

Eligibility criteria:
inclusion criteria: 1. forced expiratory volume in 1 second (fev1) between 30 - 90%. 2. no respiratory exacerbations during the last 2 weeks before the start of the study 3. not have clotting problems or a history of bleeding diathesis 4. patients with liver function abnormalities are included in the study exclusion criteria: 1. pregnant women or those not using contraception. 2. known allergy to fish and / or seafood.
evaluation of patients with rapid cycling bipolar disorder (rcbd)

Conditions: Bipolar Disorder; Rapid Cycling Bipolar Disorder

Summary: bipolar disorder is a mood (affective) disorder characterized by the occurrence of alternating feelings of excitement (mania) and depression. it is a common, but serious condition, and potentially life-threatening. patients are considered to have a rapid cycling form of bipolar disorder if they experience four or more episodes of hypomania (mild degree of mania), mania, and/or depression. approximately 20% of the patients in bipolar clinics have the rapid cycling form of the disorder. therefore it can be said that rcbd is not a rare condition and that it can severely impair a patient. these reasons alone justify studying rcbd. however, researchers also believe that information gathered by studying patients with rcbd can be used while studying other patients with different forms of bipolar disorder. the purpose of this study is to screen patients diagnosed as having rapid cycling bipolar disorder to see if they fit the criteria for the diagnosis and to see if they would be interested in participating in other research studies. patients will undergo diagnostic interviews, physical examination, routine blood tests, ekg (electrocardiogram), and complete self-rating forms as part of the screening process.

the purpose of this protocol is to allow for the medical and psychiatric screening of patients with rapid cycling bipolar disorder in order to ascertain (1) that they fit the criteria for the diagnosis; and (2) that they are interested in participating in one of our research projects. patients will undergo diagnostic interviews, complete self-rating forms, and have a physical examination, routine blood tests, and an electrocardiogram.

Eligibility criteria:
must be currently in treatment with a psychiatrist. subjects must not have borderline or antisocial personality disorders, must not meet criteria for substance abuse or dependence within the past six months. subjects must not have significant hepatic, renal, endocrine, or cardiovascular disease. subjects must not be pregnant.

Keywords: bipolar disorder rapid cycling screening
preventing repeat hospitalisations in patients with chronic obstructive pulmonary disease (copd)

Conditions: Chronic Obstructive Pulmonary Disease (COPD)

Summary: the purpose of this study is to determine whether the investigators can predict which patients are at risk of a re-exacerbation of copd within 30 and 90 days using changes in lung capacity during the initial exacerbation.

patients admitted to hospital with an acute exacerbation of copd will be approached to participate in the study. the investigators will analyse changes in lung capacity (through measurement of spirometry and inspiratory capacity) and physical activity level over the first three days of admission, at discharge and at a day 30 follow-up visit. the investigators will record quality of life and symptom scores at these time points and again at a day 90 telephone visit. data relating to the patients overall health status -disease severity, co-morbidity, cognition, psychological status, home environment and adherence to inhaled medication will be collected. the investigators will look for any relationship between these changes and a further exacerbations within 30 and 90 days. the central hypothesis of this proposal is that the clinical course following an exacerbation of copd may be monitored through measurement of inspiratory capacity(ic), a marker of lung hyperinflation. resolution of an exacerbation is related to an increase in inspiratory capacity above a threshold level of improvement, after which the risk of re-exacerbation within the subsequent 30 and 90 days is low. the investigators will assess the accuracy of ic as a predictor of exacerbation and the feasibility of measuring ic during the early stages of a copd exacerbation.

Eligibility criteria:
inclusion criteria: * within 72 hours of admission with an acute exacerbation of copd (ae copd) defined as "an acute change in a patient's baseline dyspnoea, cough and/or sputum beyond day-to-day variability sufficient to warrant a change in therapy" as per ats/ers consensus guidelines\[ \] where "a change in therapy" includes the following: prescription of antibiotics and / or systemic steroids * diagnosis of copd based on gold criteria * able to give informed consent * willing to participate in the study exclusion criteria: * admission reason other than ae copd or breathlessness primarily caused by another pathology * already enrolled in the study * receiving palliative care * severe cognitive impairment or psychological disorder that results in inability to give informed consent or complete investigations required for the study * physical impairment resulting in inability to complete physiological tests

Keywords: acute exacerbation of copd clinical problems in copd